Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening...
Associate Professor David Godler is a Principal Fellow at the University of Melbourne, group leader of the Diagnosis and Development Laboratory at the Murdoch Children’s Research Institute (MCRI) and is on the executive of the Genomic Screening Consortium for Australian Newborns (GenSCAN). He has completed his PhD in 2007 at the Department of Medicine, Monash University in genetics and immunology, then undertook post-doctoral studies on epigenetic disorders associated with chromosomal abnormalities and developmental delay in the laboratory of Professor Andy Choo. He was later appointed senior postdoctoral fellow at the Victorian Clinical Genetics Services (VCGS) and MCRI, demonstrating strong evidence of innovation and research translation. To date he has been named as an inventor on 6 patent families (with more than 40 patent filings), including 16 granted patents, related to technologies developed for different diagnostic and screening applications, He has 59 publications (41 as 1st or last author) in such quality journals as Genetics in Medicine (X4), Clinical Chemistry (X3), Neurology (X2), JAMA Neurology (X1), JAMA Network Open (X1) and Molecular Autism (X1). In 2018, he was awarded a Next Generation Clinical Researchers Program - Career Development Fellowship, focusing on improved diagnosis, natural history studies and clinical trials for neurodevelopmental disorders associated with intellectual disability and autism. In 2020 he established and currently leads the Australian first Chromosome 15 imprinting Disorders national biobank. In 2022 he was awarded a 5-year program funding from the Genomics Health Futures Mission, the Medical Research Future Fund. This program aims to assess benefits of extended epi-genomic newborn screening workflow developed by his group on 100,000 infants recruited into a $55 million funded whole-of-state birth cohort called Generation Victoria (https://www.genv.org.au/for-researchers/current-genv-collaborations/).
Top Publications
Cornish, KM, Kraan, CM, Bui, QM, Bellgrove, MA, Metcalfe, SA, Trollor, JN, Hocking, DR, Slater, HR, Inaba, Y, Li, X, et al.
Novel methylation markers of the dysexecutive-psychiatric phenotype in FMR1 premutation women..
Neurology
84(16)
:
1631 -1638
2015
view publication
Shelton, AL, Cornish, KM, Godler, DE, Clough, M, Kraan, C, Bui, M, Fielding, J.
Delineation of the working memory profile in female FMR1 premutation carriers: the effect of cognitive load on ocular motor responses..
Behav Brain Res
282:
194 -200
2015
view publication
Hocking, DR, Kraan, CM, Godler, DE, Bui, QM, Li, X, Bradshaw, JL, Georgiou-Karistianis, N, Metcalfe, SA, Archibald, AD, Turbitt, E, et al.
Evidence linking FMR1 mRNA and attentional demands of stepping and postural control in women with the premutation..
Neurobiol Aging
36(3)
:
1400 -1408
2015
view publication
Birch, RC, Hocking, DR, Cornish, KM, Menant, JC, Georgiou-Karistianis, N, Godler, DE, Wen, W, Hackett, A, Rogers, C, Trollor, JN.
Preliminary evidence of an effect of cerebellar volume on postural sway in FMR1 premutation males..
Genes Brain Behav
14(3)
:
251 -259
2015
view publication
Inaba, Y, Schwartz, CE, Bui, QM, Li, X, Skinner, C, Field, M, Wotton, T, Hagerman, RJ, Francis, D, Amor, DJ, et al.
Early detection of fragile X syndrome: applications of a novel approach for improved quantitative methylation analysis in venous blood and newborn blood spots..
Clin Chem
60(7)
:
963 -973
2014
view publication